I
Infinity Pharmaceuticals
Discovery and development of medicines for the treatment of cancer and related conditions
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative cancer therapies. The company primarily targets the immune system to treat advanced melanoma and other malignancies. Operating in the biotechnology sector, Infinity Pharmaceuticals serves patients with severe cancer conditions, collaborating with leading medical institutions and researchers. The company’s business model revolves around the research, development, and commercialization of novel drugs. Revenue is generated through the sale of approved therapies and partnerships with other pharmaceutical companies. Infinity Pharmaceuticals leverages its scientific expertise and strategic collaborations to advance its drug pipeline, aiming to bring life-saving treatments to market.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2001
- Headquarters
- Cambridge, United States
- Listing
- IPO 2009
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Advent Life Sciences
Venrock- VVVulcan Medical Ventures
HBM Healthcare Investments- PPProspect Venture Partners
Wellcome Trust
Novartis Venture Fund
Series B and later3 investors entered at this stage
Amgenbd
Purdue Pharma
Amgen Ventures
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Infinity Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Infinity Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.